header logo image

Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

September 29th, 2022 1:49 am

Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Read the original here:
Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick